How Much Weight Should I Expect to Lose on Wegovy?

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, produced an average weight loss of 15 pounds over the first month in early trial phases, with cumulative losses reaching 35–52 pounds by week 68. Real-world outcomes depend on your starting weight, metabolism, and commitment to diet and exercise. This guide explores what peer-reviewed research shows about weight loss trajectories and how PlexusDx compounded semaglutide can deliver comparable clinical benefits at a lower cost.

Average Weight Loss on Semaglutide: Clinical Trial Data

The STEP trials, which tracked over 4,500 participants, documented consistent weight loss patterns across different semaglutide doses. Patients receiving 2.4 mg weekly lost an average of 22% of their baseline body weight—roughly 15–20 pounds per month initially, then stabilizing as the body adapts. For someone weighing 250 pounds, this translates to approximately 55 pounds over the full trial period. Results peaked around week 52 and remained stable through week 68, suggesting that continued treatment maintains rather than accelerates loss.

Not all weight loss happens at the same rate. Most participants experienced their steepest decline in months 1–3, when appetite suppression is most pronounced. The rate then tapers to 1–3 pounds per week by months 4–6, as your body reaches a new equilibrium. Baseline weight matters: heavier individuals often see larger absolute numbers but similar percentage reductions. A person starting at 350 pounds and a person starting at 200 pounds on the same dose may both lose roughly 20% of their weight, though the absolute figures differ significantly.

Factors That Influence Your Individual Weight Loss Results

Genetic variation plays a critical but underappreciated role in semaglutide response. Variants in the GLP1R gene, FTO gene, and MC4R gene influence how strongly your appetite-control centers respond to the medication. Someone with a favorable GLP1R variant may experience near-total appetite suppression at 0.5 mg, while another person needs 2.0 mg to achieve similar results. PlexusDx offers the Precision Peptide Genetic Test to map your 14 appetite and weight-regulation pathways, identifying which compounds and doses align with your genetic profile. This personalization cuts trial-and-error by weeks and optimizes your monthly investment.

Lifestyle adherence matters as much as medication potency. Semaglutide suppresses hunger but does not prevent eating; you must still choose nourishing foods and maintain a calorie deficit. Studies show that patients combining medication with structured nutrition counseling and exercise lose 5–10 pounds more than those taking semaglutide alone. Stress, sleep deprivation, and inconsistent meal timing also blunt results. Age, thyroid function, and prior weight-loss attempts add another layer of individual variation. PlexusDx treatment plans work best alongside a registered dietitian or health coach who can reinforce behavioral change.

Timeline: When to Expect Weight Loss Results on Semaglutide

Week 1–2: Most users report reduced appetite and food cravings within 24–48 hours of the first injection. Weight loss during this phase is minimal—typically 1–3 pounds—and partly due to reduced water retention and glycogen depletion rather than fat loss. You may notice less interest in snacks, larger portions feeling uncomfortably full, and a shift in food preferences away from sugary or fatty options.

Month 1–3: This is the most dramatic phase. Average weight loss accelerates to 3–5 pounds per week as your calorie intake drops by 300–500 calories daily. By the end of month three, most users have shed 15–25 pounds. Energy levels often improve despite eating less because blood sugar stabilizes and inflammation decreases. Your clothes fit differently, and people around you may begin commenting on your appearance.

Month 4–6: Weight loss plateaus slightly to 1–3 pounds per week as your metabolism adapts and appetite suppression remains steady but not intensifying. Total loss by month six often reaches 30–45 pounds. Some users experience temporary plateaus lasting 1–2 weeks; this is normal and does not signal failure. Dose escalation, if indicated by your PlexusDx provider, can restart downward momentum.

Comparing Wegovy, Ozempic, and PlexusDx Compounded Semaglutide

Wegovy (semaglutide 2.4 mg weekly) and compounded semaglutide contain the same active molecule, produced by the same licensed 503A compounding pharmacies as PlexusDx. The clinical weight loss outcomes are identical because the peptide is biochemically identical. The key difference is cost and accessibility. Branded Wegovy typically costs $900–$1,300 per month with commercial insurance or out-of-pocket; uninsured patients often pay list price. PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) flat—no flat per-compound pricing increases, no insurance required, and HSA/FSA eligible.

Ozempic (semaglutide for diabetes) and Wegovy are manufactured by the same company but marketed separately; Ozempic uses lower starting doses designed for blood-sugar control rather than weight loss. Some patients and providers use Ozempic off-label for weight loss, but it typically costs $100–$300 monthly with insurance and reaches lower final doses than Wegovy. PlexusDx allows you to start low and titrate up to your clinical sweet spot, mirroring Wegovy's protocol without the pharmacy chain markup. All three options can achieve similar 20%+ weight loss if you stay adherent.

Managing Expectations: Realistic Goals and Long-Term Outcomes

A sustainable weight loss goal on semaglutide is 10–20% of your starting body weight over 6 months. This range aligns with clinical trial data and reduces the risk of metabolic adaptation or muscle loss. Someone weighing 250 pounds should aim for a loss of 25–50 pounds by month six, not 100 pounds. Faster loss sometimes reflects dehydration or muscle breakdown rather than fat, which can slow metabolism long-term. PlexusDx providers guide you toward a pace that feels sustainable and preserves lean mass, especially if you combine semaglutide with resistance exercise.

Weight regain is common after stopping semaglutide; studies show that 70% of lost weight returns within one year if the medication ends and lifestyle changes don't persist. This is not failure—it reflects the chronic, relapsing nature of obesity and the biological power of your appetite-control circuits. Many successful patients view semaglutide as a long-term maintenance tool, like blood pressure or cholesterol medication, rather than a temporary fix. PlexusDx's monthly pricing model ($189 starting cost) makes ongoing treatment affordable and accessible for those committed to sustained weight management.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight will I lose in the first month on semaglutide?

Most people lose 5–15 pounds in the first month, with the steepest decline occurring in weeks 2–4 as appetite suppression kicks in. Results vary based on starting weight, genetics, and adherence to a calorie deficit. PlexusDx providers monitor your progress and adjust dosing if needed to optimize your outcome.

Is 22% weight loss realistic for someone like me?

The 22% average from STEP trials is achievable but not guaranteed. Your individual result depends on genetic factors (which PlexusDx can identify via the Precision Peptide Genetic Test), baseline weight, lifestyle consistency, and medication adherence. Realistic targets range from 10–20% over six months for most users.

Why does semaglutide cost so much with insurance or at retail pharmacies?

Branded Wegovy prices reflect pharmaceutical company markups, pharmacy chain profits, and insurance administration. PlexusDx sources from licensed 503A compounding pharmacies, cutting out middlemen, and passes savings directly to you—at $189/mo month-to-month, or from $149/mo on the 6-month plan flat with no dose-based increases.

Can I lose weight faster by taking higher doses of semaglutide?

Higher doses may increase appetite suppression but also raise the risk of gastrointestinal side effects like nausea and vomiting, which can reduce adherence. Clinical trials show that 2.4 mg is the optimal maintenance dose for weight loss; jumping ahead rarely accelerates results and often backfires. PlexusDx providers titrate gradually to find your best dose-response balance.

How does the Precision Peptide Genetic Test help me lose more weight?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.